FDA grants priority review for Sanofi’s venglustat NDA
If approved, venglustat would be the first treatment in the US to address the neurological symptoms of GD3, which currently have no targeted therapies. The decision is anticipated
Helicons are stabilised, cell-penetrant alpha-helical peptides engineered to interact with intracellular protein targets, including those with flat surfaces unsuitable for traditional small molecule engagement. The partnership will investigate